Alvimopan (Adolor/GlaxoSmithKline).
Alvimopan is a potent, peripherally active, mu-opioid receptor antagonist being developed by Adolor and GlaxoSmithKline (GSK) as a potential treatment for post-operative ileus and opioid bowel dysfunction.
Azodo
Ijeoma A
IA
University of Chicago, Department of Medicine, IL 60637, USA.
Ehrenpreis
Eli D
ED
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D009292:Narcotic Antagonists; D010880:Piperidines; D017450:Receptors, Opioid, mu; C419502:alvimopan